HC Wainwright restated their buy rating on shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) in a research report report published on Wednesday morning. HC Wainwright currently has a $6.00 price objective on the medical research company’s stock.

A number of other research analysts have also weighed in on HTGM. ValuEngine raised shares of HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research note on Monday, July 17th. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a sell rating to a hold rating in a research note on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $6.17.

HTG Molecular Diagnostics (NASDAQ HTGM) remained flat at $$2.38 on Wednesday. The company had a trading volume of 382,100 shares, compared to its average volume of 1,151,226. HTG Molecular Diagnostics has a 1-year low of $1.20 and a 1-year high of $13.25.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/htg-molecular-diagnostics-inc-htgm-stock-rating-reaffirmed-by-hc-wainwright/1698591.html.

In other news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $1.81, for a total transaction of $2,081,161.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 1,661,889 shares of company stock valued at $3,077,980 in the last 90 days. Insiders own 7.60% of the company’s stock.

A hedge fund recently raised its stake in HTG Molecular Diagnostics stock. Vanguard Group Inc. lifted its position in shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) by 38.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 135,234 shares of the medical research company’s stock after buying an additional 37,841 shares during the period. Vanguard Group Inc. owned approximately 1.42% of HTG Molecular Diagnostics worth $359,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 21.69% of the company’s stock.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.